 |
 |
Instructions for Authors
- Page Path
-
- HOME
- FOR CONTRIBUTORS
- Instructions for Authors
 |
2019 |  |
 |
2017 |  |
|
2015-2016 | |
|
2013-2012 | |
|
2009-2011 | |
|
2008 | |
|
2006-2007 | |
|
2005 | |
|
2004 | |
|
2003 | |
Table of Contents
- Editorial Policy
- Preparation of Manuscripts
- Submission of Manuscript
- Peer Review and Revision of Manuscripts
- Open Access Policy and Open Data Policy
- Publication Charge
|
Genomics & Informatics (Genomics Inform) is owned and published by the Korea Genome Organization (KOGO). It is published four times per year (Mar, Jun, Sep, and Dec) in an online version. Genomics & Informatics welcomes high-quality research papers presenting novel data on the topics of gene discovery, comparative genome analyses, molecular and human evolution, informatics, genome structure and function, technological innovations and applications, statistical and mathematical methods, cuttingedge genetic and physical mapping, and DNA sequencing and other reports that present data where sequence information is used to address biological concerns. The journal publishes papers based on original research that are judged after editorial review to make a substantial contribution to the understanding of any area of genomics or informatics. Only manuscripts written in English under the Genomics & Informatics author guidelines are accepted. Genomics & Informatics follows the open access journal policy. All of the content of Genomics & Informatics is freely available online. Digital files can be read, downloaded, and printed without charge. Manuscripts for submission to Genomics & Informatics should be prepared according to the following instructions. Genomics & Informatics follows the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (http://www.icmje.org) from ICMJE and Principles of Transparency and Best Practice in Scholarly Publishing (joint statement by COPE, DOAJ, WAME, and OASPA; (http://doaj.org/bestpractice) if otherwise not described below. |
||||||||||||||||||||||||||||||||||||||||
| EDITORIAL POLICY | ||||||||||||||||||||||||||||||||||||||||
|
Copyright: The regulations for acceptance of a manuscript for publication automatically include the consent of the author(s) to transfer the copyright or license to KOGO. Authors should complete a Copyright Agreement Form (CAF) at the time of proofreading. The corresponding author can sign on behalf of any co-authors. The CAF can be obtained from the editorial office. Acceptance of the agreement will ensure full copyright protection and help to disseminate the article to the widest possible readership in print and electronic formats. The authors are responsible for obtaining permission to reproduce copyrighted material from other sources. Disclaimer: The publisher, editors, and reviewers do not assume any legal responsibility for errors, omissions, or claims, nor do they provide any warranty, expressed or implied, with respect to information published in Genomics & Informatics Ethics: Research published in Genomics & Informatics must have been conducted in accordance with institutional, national, and international guidelines concerning the use of animals in research and/or the sampling of endangered species. For the policies on research and publication ethics that are not stated in these instructions, the Good Publication Practice Guidelines for Medical Journals (http://kamje.or.kr/intro.php?body=publishing_ethics) and the Guidelines on Good Publication (http://publicationethics.org/resources/guidelines) can be applied. The Editor-in-Chief reserves the right to reject manuscripts that do not comply with the aforementioned requirements. The author will be held responsible for false statements or failure to fulfill the aforementioned requirements. Statement of Informed Consent: Copies of written informed consent and Institutional Review Board (IRB) approval for clinical research should be kept. If necessary, the editor or reviewers may request copies of these documents to resolve questions about IRB approval or study conduct. Statement of Human and Animal Rights: All human investigations must be conducted according to the principles expressed in the Declaration of Helsinki. All studies involving animals must state that the guidelines for the use and care of laboratory animals of the authors’ institution, or of any national law, were followed. Registration of clinical trial research: Any research that deals with a clinical trial should be registered with the primary national clinical trial registry site, such as the Korea Clinical Research Information Service (CRiS, http://cris.nih.go.kr), other primary national registry sites accredited by the World Health Organization (http://www.who.int/ictrp/network/primary/en/), or ClinicalTrials.gov (http://clinicaltrials.gov/), a service of the United States National Institutes of Health. Authorship: All authors must have participated in the research and/or article preparation. The corresponding author is responsible for ensuring that all individuals included as authors on a manuscript must (1) agree to be listed; (2) have contributed to the research reported; and (3) approve the submitted version of the manuscript. The corresponding author should be prepared to explain the presence and order of these individuals. The statement that all authors have approved the final article should be true and be included in the disclosure. Conflict of Interest Statement: The corresponding author must inform the editor of any potential conflicts of interest that could influence the authors’ interpretation of the data. Examples of potential conflicts of interest are financial support from or connections to pharmaceutical companies, political pressure from interest groups, and academically related issues. In particular, all sources of funding applicable to the study should be explicitly stated. As a guideline, any affiliation associated with a payment or financial benefit exceeding $10,000 per annum or 5% ownership of a company or research funding by a company with related interests would constitute a conflict that must be declared. This policy applies to all submitted research manuscripts and review material. Originality and Duplicate Publication: No part of the accepted manuscript should be duplicated in any other scientific journal without the permission of the Editorial Board. If duplicate publication or plagiarism related to the papers of this journal is detected, the authors will be announced in the journal, their institutes will be informed, and the authors will be penalized. All submitted manuscripts are screened by CrossCheck (Similarity Check), a plagiarism detection program provided by iThenticate. The authors assure that no substantial part of the work has been published or is being considered for publication elsewhere. When any of the results is to appear in another journal, details must be submitted to the Editor-in-Chief, together with a copy of the other paper(s) and the expected date(s) of publication. Secondary Publication: It is possible to republish manuscripts if the manuscripts satisfy the condition of secondary publication of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals by the International Committee of Medical Journal Editors (ICMJE), available from http://www.icmje.org/. These are:
|
||||||||||||||||||||||||||||||||||||||||
| PREPARATION OF MANUSCRIPTS | ||||||||||||||||||||||||||||||||||||||||
|
General Requirement Authors are recommended to keep the length of papers below 10 printed pages (30 typed pages of manuscript, including figures and tables) for original articles, four printed pages for research communications, and two printed pages (approximately 1,400 words or 1,000 words plus one figure) for application notes. All sections of the typescript should be double-spaced on one side of A4 paper (210 × 297 mm), and all pages must be numbered in order. Manuscript Type •Original Articles Original research articles are full scientific reports of original research. The manuscript should be organized as follows: Title Page, Abstract & Keywords, Introduction, Methods, Results, Discussion, Acknowledgments, References, Tables, and Figure Legends. The Results and Discussion can be combined. •Application Notes Application notes are short communications about novel software, new algorithm implementations, databases, and network services (web servers and interfaces). The manuscripts include the following: Title Page, Abstract & Keywords, Availability, Introduction, Main Text, References, and Supplementary Information. •Clinical Genomics Clinical genomics is for a short report of all kinds of genome analysis data from clinical fields, such as cancer, diverse complex diseases, and genetic diseases. Especially, Genomics & Informatics would encourage submitting cancer panel analysis data for a single cancer patient or a group of patients. Genomics & Informatics also would encourage depositing genome data into the Genomics & Informatics database. The manuscript should be organized as follows: Title Page, Abstract & Keywords, Introduction, Methods, Results, Discussion, Acknowledgments, References, Tables, and Figure Legends. The Introduction, Methods, Results, and Discussion can be combined. •Genome Archives Genome Archives is for a short manuscript announcing the genetic information of recently sequenced prokaryotic and eukaryotic genomes. Genomics & Informatics would encourage depositing the genome data into the Genomics & Informatics database. These genome archive data can make the rationale for sequencing a specific organism. The manuscript should be organized as follows: Title Page, Abstract & Keywords, Introduction, Methods, Results, Discussion, Acknowledgments, References, Tables, and Figure Legends. The Introduction, Methods, Results, and Discussion can be combined. •Letters to the Editor Critical comments are welcomed for correcting errors of published facts and for providing alternative interpretations of published data. The sequence for a Letter to the Editor is the following: Title Page, Text, References, and Names and Affiliations of Authors. If needed, tables and figures can be included. A Letter to the Editor should not be longer than a printed page. •Review Articles Review Articles are usually solicited by the Editor-in-Chief. Authors wishing to prepare a review article should contact the Editor-in-Chief to discuss the suitability of the subject for the journal. There is no specific requirement for subsections of the body text of the paper. Manuscript Format Title: The title page should include (1) the full names of all authors with their Open Researchers and Contributors ID (ORCID), and the name(s) and address(es) of the institution(s) at which the work was carried out; (2) the telephone and fax numbers, and the E-mail address of the corresponding author; and (3) a running title of no more than 50 characters, including spaces. Place an asterisk (*) after the corresponding author. Abstract: The abstract should be unstructured and a single paragraph of fewer than 250 words. References should not be cited in the abstract. Six or fewer keywords should be appended to the abstract in alphabetical order. When possible, the keywords should be those found in the Medical Subject Headings of Index Medicus. Main text: All papers should be divided into the following sections and appear in this order:
(1) Introduction: The paper begins with an introduction without subheadings that reviews the literature and states and justifies the purpose of the research.
Authors’ contribution: If the number of authors is equal to or greater than two, the authors’ roles should be described according to their specific role. Genomics & Informatics participates in the CRediT standard for author contributions. The contributions of all authors must be described using the CRediT Taxonomy of author roles. For each of the categories below, please enter the initials of the authors who contributed in that category. If listing more than one author in a category, separate each set of initials with a space. If no one contributed in a category, you may leave that box blank. The corresponding author is responsible for completing this information at submission, and it is expected that all authors will have reviewed, discussed, and agreed to their individual contributions ahead of this time.(2) Methods: This section should contain sufficient detail so that all procedures can be repeated, in conjunction with the cited references. The manufacturer and model number should be stated in this section—for example, as Sigma Chemical Co. (St. Louis, MO, USA). (3) Results: This section should describe the results of the experiments. Extensive interpretation should be reserved for the Discussion section. The results should be presented as concisely as possible. Footnotes should not be used and will be transferred to the text. Gene symbols should be italicized; protein products are not italicized. (4) Discussion: This section should provide an interpretation of the results in relation to previously published work and to the experimental system at hand. The Results and Discussion may be combined. (5) Acknowledgments: Information concerning the sources of financial support should be included in the acknowledgments. Conceptualization: AB Data curation: EFG Formal analysis: AB Funding acquisition: CD Methodology: AB, CD, EFG Writing – original draft: AB, EFG Writing – review & editing: AB, CD, EFG Reference: The references should include only articles that are published or in press. Unpublished data, submitted manuscripts, abstracts, and personal communications should be cited within the text only. References are to be numbered in the order of citation within the article in brackets. References with up to six authors must list all names; for more than six authors, the first six names should be listed, followed by “et al.” Journal name titles should be abbreviated in accordance with the NLM Catalog, available from: https://www.ncbi.nlm.nih.gov/nlmcatalog/journals, or the ISO 4 standard, available from: http://www.issn.org/services/online-services/access-to-the-ltwa/?letter=a. Examples of references are given below:
Journal article
Tables and Figures: Figure legends and tables should be included in the submitted manuscript as separate sections and should be formatted following the style of the journal. Each figure legend should have a brief, separate title that describes the entire figure without citing specific panels. The manuscript should be submitted with a set of figures of sufficient quality for reviewers to judge the data. All figures may be provided in color for the electronic version of the journal, even if the print version is in black and white. Figures will be printed in color only when in the reviewers' opinions the color is essential.- Park J, Lappe M, Teichmann SA. Mapping protein family interactions: intramolecular and intermolecular protein family interaction repertoires in the PDB and yeast. J Mol Biol 2001;307:929-938. - Cho SM, Jung SH, Chung YJ. A variant in RUNX3 is associated with the risk of ankylosing spondylitis in Koreans. Genomics Inform 2017;15:65-68. - Thomas PD, Campbell MJ, Kejariwal A, Mi H, Karlak B, Daverman R, et al. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res 2003;13:2129-2141. Books - Cowan WM, Jessell TM, Zipursky SL. Molecular and Cellular Approaches to Neural Development. New York: Oxford University Press, 1997. Book sections - Sorenson PW, Caprio JC. Chemoreception. In: The Physiology of Fishes (Evans DH, ed.). Boca Raton: CRC Press, 1998. pp. 375-405. Online document - Puniyani AR, Lukose RM. Growing random networks under constraints. Ithaca: Cornell University Library, 2001. Accessed 2011 Oct 3. Available from: http://xxx.lanl.gov/abs/cond-mat/0107391. Conference paper - Han H. Nonnegative principle component analysis for mass spectral serum profiles and biomarker discovery. In: The 8th Asia-Pacific Bioinformatics Conference (Parida L, Myers G, eds.), 2010 Jan 18-21, Bangalore. Dissertation/Thesis - Hwang KB. Hierarchical probabilistic graphical models for large-scale data analysis. Ph.D. Dissertation. Seoul: Seoul National University, 2005. Photographs and illustrations should be of professional quality. Images should be provided as TIFF files. JPEG is also acceptable when the original format is JPEG. Each figure must be of 300 dpi or higher resolution with good contrast and sharpness. If a figure is to be reduced, all elements, including labels, should be able to withstand reduction and remain legible. Electron and light microscopic figures must be original or scanned copies from the original. The magnification should be indicated on each micrograph with a scale bar. Tables are to be organized in portrait view and may run, if necessary, to subsequent pages in the vertical direction only. Tables should be designed for printing within two (17.5 cm) columns of width in no less than 10-point font and should not exceed more than the width of a journal page. If a table does not fit into this format, consider shortening row or column labels, using more than one table to display the data, eliminating unnecessary data, or converting table data into a figure or transferring part of the table data to the supplement. Scientific Names: The full formal Latin name for a taxon (e.g., Homo sapiens ) should be provided the first time that the taxon is mentioned and should be italicized. In subsequent sentences, the scientific name of all taxa in the same genus should be abbreviated to the first initial of the generic name and the species name (e.g., H. sapiens), except where this usage creates confusion or ambiguity. When common names are used, the scientific name should be provided the first time the taxon is mentioned in the abstract and again the first time that taxon is mentioned in the main manuscript [e.g., “red pine (Pinus densiflora)...”]. Other taxonomic designations (e.g., family names) should not be italicized, and common names should not be capitalized. Units and Equations: Standard metric units should be used for describing length, height, weight, and volume. The unit of temperature is given in degrees Celsius (°C). All others are in terms of the International System of Units (SI). All unit symbols must be preceded by one space except percentage (%) and temperature (°C). All equations should be numbered in Arabic numerals. Abbreviations: Abbreviations must be used as an aid to the reader, rather than as a convenience of the author, and therefore, their use should be limited. Generally, avoid abbreviations that are used less than 3 times in the text, including the tables and figure legends. In addition to abbreviations for SI units, common molecular, chemical, immunological, and hematological terms can be used without definition in the title, abstract, text, tables, and figure legends—e.g., bp, kb, kDa, DNA, cDNA, RNA, mRNA, and PCR. Other common abbreviations are as follows (the same abbreviations are used for plural forms): h (hour; use 0-24:00 h for time), s (second), min (minute), day (not abbreviated), week (not abbreviated), month (not abbreviated), year (not abbreviated), L (liter), mL (milliliter), μL (microliter), g (gram), kg (kilogram), mg (milligram), μg (microgram), ng (nanogram), pg (picogram), g (gravity; not ×g), n (sample size), SD (standard deviation of the mean), and SE (standard error of the mean). Supplementary Materials: Supplementary materials can be provided to support and enhance scientific information. Supplementary files offer additional possibilities for publishing supporting applications, sequence alignment, background datasets, microarray hybridization experiments, high-resolution images, movies, sound clips, and more. Supplementary files will be published alongside the online version of the article on the Genomics & Informatics web site. This material will not be edited or formatted; thus, the authors are responsible for the accuracy and presentation of all such material. Accepted file formats for supplementary materials:
File sizes must be as small as possible, for quick downloading. Recommended specifics are:
Please seek advice from the editorial office before sending files larger than our recommended size to avoid delays in publication. Accession Numbers: Please provide accession numbers for any new data (SNPs, gene sequences, protein sequences, CNVs, microarray data, or structures), which must be deposited in the appropriate genome- or locusspecific database, in a separate section entitled “Accession Numbers,” following the Web Resources section (or the Acknowledgments section if no online resources or appendices have been used), directly above the reference list. Please use the following format to list accession numbers: “The accession number(s) for the _______ sequence(s) reported in this paper is/are [database]: [accession number].” |
||||||||||||||||||||||||||||||||||||||||
| SUBMISSION OF MANUSCRIPT | ||||||||||||||||||||||||||||||||||||||||
| The manuscript should be submitted in MS Word file format. The recommended font is Times New Roman with a 12-point font size. All manuscripts must be submitted online through the Genomics & Informatics e-submission system at http://submit.genominfo.org. Any questions concerning manuscript submission should be directed to: Editor, Genomics & Informatics, Korea Genome Organization, Room No. 806, 193 Mallijae-ro, Jung-gu, Seoul 04501, Korea (http://www.kogo.or.kr, Tel: +82-2-558-9394, Fax: +82-2-558-9434, E-mail: kogo@kogo.or.kr). | ||||||||||||||||||||||||||||||||||||||||
| PEER REVIEW AND REVISION OF MANUSCRIPT | ||||||||||||||||||||||||||||||||||||||||
|
Peer Review A manuscript is generally reviewed by at least two peer reviewers qualified to evaluate the manuscript. It is a blind peer review. An initial decision will normally be made within one month of receipt of a manuscript. A manuscript that has been published or of which a substantial portion has been published elsewhere will not be accepted. The Editor-in-Chief is responsible for final decisions regarding the acceptance of a peer-reviewed paper. Manuscript Revision When a manuscript is returned to the corresponding author for revision, the reviewed manuscript must be re-submitted within one month, unless the authors request an extension. A galley proof and reprint order form will be sent to the corresponding author. The corresponding author is responsible for communicating with the other authors about revisions and final approval of the proofs. The first proofreading is the author’s responsibility, and the proof should be returned within three days from the date of receipt. |
||||||||||||||||||||||||||||||||||||||||
| OPEN ACCESS POLICY AND OPEN DATA POLICY | ||||||||||||||||||||||||||||||||||||||||
|
Open Access Policy Genomics & Informatics is an open access journal. Articles are distributed under the terms of the Creative Commons Attribution Non-Commercial license (http://creativecommons. org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited for non-commercial purposes. To use the tables or figures of Genomics & Informatics in other periodicals, books, or media for scholarly, educational, or even commercial purposes, the process of permission request to the Publisher is not necessary. This is in accordance with the Budapest Open Access Initiative definition of open access. It also follows the open access policy of PubMed Central at the United States National Library of Medicine (http://www.ncbi.nlm.nih.gov/pmc/) and ScienceCentral, maintained by the Korean Federation of Science and Technology Societies (http://www.e-sciencecentral.org/). All of the content of the journal is available immediately upon publication without an embargo period. Archiving Policy Full text of Genomics & Informatics has been archived in PubMed Central (PMC)/Europe PMC/PMC Canada (https://www.ncbi.nlm.nih.gov/pmc/journals/1928/) since 2012. Deposit policy (Self-archiving policy) according to Sherpa/Romeo (http://www.sherpa.ac.uk/): Author can not archive pre-print (i.e., pre-refereeing). Author can archIve post-print (i.e., final draft post-refereeing). Author can archive publisher’s version/PDF. Open Data Policy Genomics & Informatics also follows the open data policy according to PLoS One data availability (http://journals.plos.org/plosone/s/data-availability). For clarification on result accuracy and the reproducibility of results, raw data, including nucleic acid and protein sequences, as well as X-ray crystallographic coordinates or analysis data produced during the experiments, should be submitted to the journal or deposited to a public repository—for example, United States National Center of Biological Information (NCBI) or Harvard Dataverse (https://dataverse.harvard.edu)—and the address should be described in the Results section. If the data are already public, the URL site or sources should be disclosed. If data can not be publicized, it can be negotiated with the editor. If there are any inquiries on depositing data, author s should contact the editorial office. Clinical Data Sharing Policy This journal follows the data sharing policy described in “Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors” (https://doi.org/10.3346/jkms.2017.32.7.1051). As of July 1, 2018, manuscripts submitted to ICMJE journals that report the results of clinical trials must contain a data sharing statement as described below. Clinical trials that begin enrolling participants on or after January 1, 2019 must include a data sharing plan in the trial's registration. The ICMJE's policy regarding trial registration is explained at www.icmje.org/recommendations/browse/publishingand-editorial-issues/clinical-trial-registration.html. If the data sharing plan changes after registration, this should be reflected in the statement submitted and published with the manuscript and updated in the registry record. Data sharing statements must indicate the following: whether individual deidentified participant data (including data dictionaries) will be shared; what data in particular will be shared; whether additional, related documents will be available (e.g., study protocol, statistical analysis plan, etc.); and when the data will become available and for how long; by what access criteria data will be shared (including with whom, for what types of analyses, and by what mechanism). Illustrative examples of data sharing statements that would meet these requirements are in Table 1. Table 1. Examples of data sharing statements that fulfill ICMJE requirementsa
ICMJE, International Committee of Medical Journal Editors. aThese examples are meant to illustrate a range of, but not all, data sharing options. Detailed Description of Use of Articles of Genomics & Informatics Reader Benefit: Publisher applies the Creative Commons Attribution Non-Commercial license to works it publishes and allows free immediate access to, and unrestricted reuse of, original works of all types. Reuse Benefit: Publisher applies the Creative Commons Attribution Non-Commercial license to works it publishes and allows free immediate access to, and unrestricted reuse of, original works of all types. Copyrights: Publisher applies the Creative Commons Attribution Non-Commercial license to works it publishes. Under this license, although publisher retains ownership of the copyright for content, it allows anyone to download, reuse, reprint, modify, distribute, and/or copy the content. Author Posting Benefit: Publisher applies the Creative Commons Non-Commercial Attribution license to works it publishes. Under this license, although publisher retains ownership of the copyright for content, it allows anyone, including author, to download, reuse, reprint, modify, distribute, and/or copy the content. Automatic Posting: Publisher immediately deposits the accepted articles in PubMed Central (http://pubmedcentral.org/), ScienceCentral (http://e-sciencecentral.org), and journal homepage (https://genominfo.org/) upon publication. Machine Readability: Genomics & Informatics articles can be accessed programmatically through PubMed Central or Europe PMC's RESTful Web Service (https://europepmc.org/RestfulWebService). For inquiries, please contact editorial office, as below: Editorial office Room No. 806, 193 Mallijae-ro, Jung-gu, Seoul 04501, Korea Tel: +82-2-558-9394 Fax: +82-2-558-9434 E-mail: kogo3@kogo.or.kr |
||||||||||||||||||||||||||||||||||||||||
| PUBLICATION CHARGE | ||||||||||||||||||||||||||||||||||||||||
| Genomics & Informatics charges US$200 (KRW200,000) for the first 7 published pages and an extra US$50 (KRW50,000) per page over 7 pages. Under exceptional circumstances, page charges will be waived if deemed appropriate by the Editorial Board. Authors unable to pay page charges may apply at the time of submission for a waiver of page charges. The color figures can still be included in the journal at no extra cost. All manuscripts accepted for publication have their English checked by a professional English editor provided by KOGO. |
- ARTICLE CATEGORY
- Editorial Office
-
Room No. 806, 193 Mallijae-ro, Jung-gu, Seoul 04501, Korea
Tel: +82-2-558-9394 Fax: +82-2-558-9434 E-mail: kogo3@kogo.or.kr
Copyright © 2024 by Korea Genome Organization.
